What Constitutes a True Hyperdense Middle Cerebral Artery Sign?Koo C.K.a · Teasdale E.a · Muir K.W.b
Departments of aNeuroradiology and bNeurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Objectives: The ‘hyperdense MCA sign’ refers to an appearance of increased attenuation of the proximal middle cerebral artery (MCA) that is often associated with thrombosis of the M1 MCA segment and may be the only diagnostic feature on computed tomography early after ischaemic stroke. False positives are recognized, and correct recognition of this sign has, therefore, assumed greater importance with the advent of thrombolytic therapy for stroke. We sought to define objective criteria for hyperdensity of the MCA. Methods: Brain computed tomographs obtained by a standard protocol in a neuroradiology department were analyzed by a single observer. All consecutive scans reported as exhibiting a hyperdense MCA were compared to controls reported as having normal scans. Ovoid regions of interest were placed over the vessels and cerebral cortices, and the attenuation in Hounsfield units (HU) measured. Absolute attenuation and ratios of one side to the other were compared. Results: MCA attenuation was unrelated to age in cases (n = 18) and controls (n = 80). The mean MCA attenuation was greater in the affected MCA of cases as compared with controls [54.0 HU (99% confidence interval CI 46.7–61.2) vs. 41.3 HU (99% CI 39.7–43.0); p < 0.00001]. Cases were subdivided into true and false positives by the ratio of denser:less dense MCA (within or without the 95% prediction interval for controls). In all true positives, the MCA ratio was > 1.2. 9 of 10 true positives had acute ischaemic stroke; 1 patient had herpes simplex encephalitis, but had MCA attenuation within the 95% CI for controls. False positives had mature cerebral infarction or non-ischaemic pathologies. The ratio of MCA attenuation to adjacent cerebral cortex was significantly higher in both true and false positives than in controls. Conclusions: Hyperdense MCAs associated with acute ischaemic stroke can be distinguished from normal vessels and false positives by measurement of absolute attenuation of affected and normal vessels: an absolute density of >43 HU and a MCA ratio of >1.2 defined hyperdensity and excluded all other pathologies. Confirmation in other centres is required.
© 2000 S. Karger AG, Basel
- Tomsick T, Brott T, Barsan W, Broderick J, Haley EC, Spiler J, Khoury J: Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR 1996;17:79–85.
- Launes J, Ketonen L: Dense middle cerebral artery sign: An indicator of poor outcome in middle cerebral artery area infarction. J Neurol Neurosurg Psychiatry 1987;50:1550–1552.
- Tomsick TA, Brott TG, Olinger CP, Barsan W, Spilker J, Eberle R, Adams H: Hyperdense middle cerebral artery: Incidence and quantitative significance. Neuroradiology 1989;31:312–315.
- Zorzon M, Masè G, Pozzi-Mucelli F, Antonutti L, Iona L, Cazzato G: Increased density in the middle cerebral artery by nonenhanced computed tomography: Prognostic value in acute cerebral infarction. Eur Neurol 1993;33:256–259.
- Von Kummer R, Meyding-Lamadé U, Forsting M, Rosin L, Rieke K, Hacke W, Sartor K: Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. AJNR 1994;15:9–15.
- Osborne DR, Bohan T, Hodson A: CT demonstration of hyperdense cerebral vasculature due to bromide therapy. J Comput Assist Tomogr 1984;8:982–984.
Hall A, Wagle V: CT enhancement after use of cocaine. AJNR 1990;11:1083.
- Rauch RA, Bazan C III, Larsson EM, Jinkins JR: Hyperdense middle cerebral arteries identified on CT as a false sign of vascular occlusion. AJNR 1993;14:669–673.
- Bastianello S, Pierallini A, Colonnese C, Brughitta G, Angeloni U, Antonelli M, Fantozzi LM, Fieschi C, Bozzao L: Hyperdense middle cerebral artery CT sign: Comparison with angiography in the acute phase of ischaemic supratentorial infarction. Neuroradiology 1991;33:207–211.
- Tomsick T, Brott T, Barsan W, Broderick J, Haley EC, Spilker J: Thrombus localisation with emergency cerebral CT. AJNR 1992;13:257–263.
- Leys D, Pruvo JP, Godefroy O, Rondepierre P, Leclerc X: Prevalence and significance of hyperdense middle cerebral artery in acute stroke. Stroke 1992;23:317–324.
- Marsman JWP, Feenstra-Holtkamp M: Dense middle cerebral artery computed tomography sign: Confirmation by magnetic resonance (MR) imaging and MR angiography. Australas Radiol 1996;40:257–260.
- Moulin T, Cattin F, Crépin-Leblond T, Tatu L, Chavot D, Piotin M, Viel JE, Rumbach L, Bonneville JF: Early CT signs in acute middle cerebral artery infarction: Predictive value for subsequent infarct locations and outcome. Neurology 1996;47:266–275.
- Hacke W, Kaste M, Fieschi C, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–1025.
- The National Institute of Neurological Disorders and Stroke rtPA Stroke Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
- Yock Jr DH: CT demonstration of cerebral emboli. J Comput Assist Tomogr 1981;5:190–196.
- Schuknecht B, Ratzka M, Hofmann E: The ‘dense artery sign’ – major cerebral artery thromboembolism demonstrated by computed tomography. Neuroradiology 1990;32:98–103.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.